Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2025 Apr 5:2024.04.26.591113.
doi: 10.1101/2024.04.26.591113.

Mimicking opioid analgesia in cortical pain circuits

Affiliations
Free PMC article

Mimicking opioid analgesia in cortical pain circuits

Corinna S Oswell et al. bioRxiv. .
Free PMC article

Abstract

The anterior cingulate cortex is a key brain region involved in the affective and motivational dimensions of pain, yet how opioid analgesics modulate this cortical circuit remains unclear. Uncovering how opioids alter nociceptive neural dynamics to produce pain relief is essential for developing safer and more targeted treatments for chronic pain. Here we show that a population of cingulate neurons encodes spontaneous pain-related behaviors and is selectively modulated by morphine. Using deep-learning behavioral analyses combined with longitudinal neural recordings in mice, we identified a persistent shift in cortical activity patterns following nerve injury that reflects the emergence of an unpleasant, affective chronic pain state. Morphine reversed these neuropathic neural dynamics and reduced affective-motivational behaviors without altering sensory detection or reflexive responses, mirroring how opioids alleviate pain unpleasantness in humans. Leveraging these findings, we built a biologically inspired gene therapy that targets opioid-sensitive neurons in the cingulate using a synthetic mu-opioid receptor promoter to drive chemogenetic inhibition. This opioid-mimetic gene therapy recapitulated the analgesic effects of morphine during chronic neuropathic pain, thereby offering a new strategy for precision pain management targeting a key nociceptive cortical opioid circuit with safe, on-demand analgesia.

PubMed Disclaimer

Conflict of interest statement

Competing interests. G.C, K.D., C.R. and G.J.S. are inventors on a provisional patent application through the University of Pennsylvania and Stanford University regarding the custom sequences used to develop, and the applications of synthetic opioid promoters (patent application number: 63/383,462 462 ‘Human and Murine Oprm1 Promotes and Uses Thereof’).

References

    1. Science. 2021 Jan 8;371(6525):153-159 - PubMed
    1. Nat Rev Drug Discov. 2017 Aug;16(8):545-564 - PubMed
    1. Brain Res. 1994 Apr 18;643(1-2):245-65 - PubMed
    1. Science. 2017 Mar 10;355(6329):1026-1027 - PubMed
    1. Front Pain Res (Lausanne). 2023 Jun 08;4:1156108 - PubMed

Publication types